FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 70462074605 Express Mail Label Number

Date of Deposit

Form PTO-1390-MOD (REV 10-96) U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER PN/4-33256A U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US)** 10/565456 **CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPRICATIONAL TOTAL													
		NATIONAL APPLICATION NO. P2004/008283	INTERNATIONAL FILING DATE 23 July 2004 (23.07.04)	PRIORITY DATE CLAIMED 25 July 2003 (25.07.03)									
TITLE OF INVENTION [23 3dlly 2004 (23.07.04)													
NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF													
		CANT(S) FOR DO/EO/US											
AUBERSON ET AL.													
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:													
1.	\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.											
2.	님	his is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.											
3.	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than dela examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39												
4.	\boxtimes	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority											
_		date.											
5.	\boxtimes	A copy of the International Application as	filed (35 U.S.C. 371(c)(2)) only if not transmitted by the Internation	ol Purocu)									
		b. As been transmitted by the Inter	national Bureau. (See Form PCT/IB/30/	ai bureau). 8)									
_	_	c. is not required, as the application	was filed in the United States Receiving	Office (RO/US).									
6. 7.	\square	A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).											
٠.	nal Bureau).												
		 b. have been transmitted by the Interest 	ernational Bureau.	·									
		c. have not been made; however, the		ts has NOT expired.									
8.		d. A translation of the amendments to the cl		71 (0)(3))									
9.		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).											
10.		A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C.											
		371(c)(5)).											
Items 11. to 16. below concern document(s) or information included.													
11.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.											
12.		An assignment document for recording.	A separate cover sheet in compliance wi	ith 37 CFR 3.28 and 3.31 is included.									
13.		A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminar	y amendment.										
	<u> </u>	·											
14.	_	An Application Data Sheet under 37 CFR	. 1.76.										
15.		A substitute specification.											
16.		A change of power of attorney and/or add	Iress letter.										
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.											
18.		A second copy of the published Internation	nal Application under 35 U.S.C. 154(d)(4).									
19.		A second copy of the English language tr	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).										

20. Other items or information: Unexecuted Declaration and Power of Attorney

U.S. APPLICATION NO					PN/4-3325	DOCKET NUMBER 56A					
The following fe			-						ULATIO	NS PTO USE	
_								ONLY			
21. 🛭 Bas	1. 🛛 Basic national fee. \$300										
☐ If Int											
23. Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$ If International Search Report was prepared and provided to the Office \$400 All other situations											
TOTAL OF 21, 22 AND 23 =											
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra			ach additional 50 or fraction d up to a whole number)	on	R/	ATE				
45 - 100 =	<u> </u>	/50 =		0		X \$	250	\$			
Surcharge of \$130 for furnishing the oath of declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).											
CLAIMS NUMBER FILED NUMBER EXTRA RATE								6			
Total claims Independent cla	aims	9	- 20 =	0	X		50 200	\$			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360											
D-44	0 for a filtra		· · · · · · · · · · · · · · · · · · ·	TOTAL OF ABOVE				\$	900		
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).											
SUBTOTAL =											
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).											
		•					AL FEE =	\$	900		
				R 1.21(h)). The assignm). \$40 per property		_	+	\$			
				TOTAL	FEE	S ENC	_OSED =	\$	900		
									ount to funded	\$	
								С	harged	\$	
a. A chec	k in the	amount of \$_		to cover the above fe	es is (enclosed.					
	Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 to cover the above fees. A duplicate copy of this form is enclosed.										
				to charge any additional fe e of Novartis.	es w	hich may	be required,	or credi	t any ove	erpayment to	
NOTE: Where or (b)) must be	an appr filed an	opriate time	limit under in restore the	37 CFR 1.494 or 1.495 ha application to pending s	as no statu:	t been me s.	et, a petition	ı to revi	ve (37 C	FR 1.137(a)	
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 Peter J. Waibel Attorney for Applicants Reg. No. 43,228 (862) 778-7951											